Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | — | — |
No symptoms reported; an adult dose of VAQTA on 07AUG2025 to a 16 year old patient.; This spontaneous report was received from a physician and refers to a 16-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. Historical vaccines included 1st dose of hepatitis a vaccine, inactivated (VAQTA), administered on 18-DEC-2024. On 07-AUG-2025, the patient was vaccinated with 2nd dose of hepatitis a vaccine, inactivated (VAQTA) suspension for injection, reported as an adult dose, administered for prophylaxis (exact dose, route of administration, anatomical location, lot# and expiry date were not reported) (overdose). No additional adverse event was reported. Lot# is being requested and will be submitted if received.